MARY OSAGIE: Open Payments
NPI 1508564097 · ORANGE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$636 in 36 payments from 9 companies in 2025. Trend: 2023 $189 · 2024 $322 · 2025 $636
Food & beverage: $636
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $205 |
| Teva Pharmaceuticals USA, Inc. | 7 | $130 |
| ABBVIE INC. | 5 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| Lundbeck LLC | 2 | $35 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: ARISTADA, REXULTI, AUSTEDO XR, VRAYLAR, CAPLYTA, UZEDY, COBENFY, Auvelity.
Industry payments across NJ — which companies pay providers there.
